Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2012
10/30/2012US8298771 Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
10/30/2012US8298769 Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
10/30/2012US8298540 Methods of modulating T cell-mediated immune responses with anti-P-selectin glycoprotein ligand 1 antibodies
10/30/2012CA2683318C Diazo bicyclic smac mimetics and the uses thereof
10/30/2012CA2682504C Aurora kinase modulators and method of use
10/30/2012CA2679915C Novel sulfonated sugar compound and use thereof as medicine
10/30/2012CA2674075C Antifolate agent combinations in the treatment of cancer
10/30/2012CA2548156C Amine derivatives
10/30/2012CA2510228C 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3
10/30/2012CA2506244C Methods for inhibiting viral replication in vivo
10/30/2012CA2360106C Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
10/26/2012WO2012145743A1 Microrna-140-5p as a tumor suppressor and sensitizing agent for chemotherapy
10/26/2012WO2012145678A1 Anti-cancer and anti-inflammatory parthenolide compounds
10/26/2012WO2012145653A2 Therapeutic combinations for use in neoplasia
10/26/2012WO2012145582A2 Methods and compositions for the specific inhibitions of egfr by double-stranded rna
10/26/2012WO2012145575A2 Therapy for leukemia
10/26/2012WO2012145535A2 Animal model of human cancer and methods of use
10/26/2012WO2012145507A2 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
10/26/2012WO2012145503A1 Pharmaceutical combinations
10/26/2012WO2012145471A1 Insulin-like growth factor-1 receptor inhibitors
10/26/2012WO2012145427A1 Methods to treat cancer using cyclosporine and cyclosporine derivatives
10/26/2012WO2012145183A2 Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
10/26/2012WO2012145125A1 Targeted radionuclides
10/26/2012WO2012144726A2 Tumor antigen proteins or genes of polo-like kinase 1
10/26/2012WO2012144716A1 Nanoparticle-based vaccine delivery system having double functions of imaging and delivery
10/26/2012WO2012144661A1 Aromatic heterocyclic derivative having trpv4-inhibiting activity
10/26/2012WO2012144579A1 Antibody preparation having solution form
10/26/2012WO2012144463A1 Therapeutic agent for tumor
10/26/2012WO2012144208A1 Diagnosis and treatment of cancer using anti-itm2a antibody
10/26/2012WO2012143879A1 A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
10/26/2012WO2012143739A1 Sonodynamic therapy
10/26/2012WO2012143725A1 Bicyclic heterocycle compounds and their uses in therapy
10/26/2012WO2012143713A2 Cancer therapy
10/26/2012WO2012143624A2 Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same
10/26/2012WO2012143599A1 Androgen receptor modulating carboxamides
10/26/2012WO2012143524A2 Bispecific antibodies against her2 and cd3
10/26/2012WO2012143523A1 Bispecifc antibodies against her2
10/26/2012WO2012143499A2 Novel binder-drug conjugates (adcs) and their use
10/26/2012WO2012143496A2 Novel binder-drug conjugates (adcs) and their use
10/26/2012WO2012143495A2 Novel binder-drug conjugates (adcs) and their use
10/26/2012WO2012143416A2 Novel compounds
10/26/2012WO2012143415A1 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
10/26/2012WO2012143413A1 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
10/26/2012WO2012143399A1 Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
10/26/2012WO2012143377A1 Niclosamide for the treatment of cancer metastasis
10/26/2012WO2012143329A1 Triazolopyridines
10/26/2012WO2012143320A1 (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
10/26/2012WO2012143248A1 Substituted pyrimidinyl-pyrroles active as kinase inhibitors
10/26/2012WO2012143143A1 Heterocyclic compounds as kinase inhibitors
10/26/2012WO2012142930A1 Anti-fatty acid synthase polypeptide and use thereof
10/26/2012WO2012142926A1 Camptothecin compound containing stable 7-membered lactone ring, preparation method and use
10/26/2012WO2012142698A1 Alkylurea derivatives active against cancer cells
10/26/2012WO2012142687A1 Antitumour testosterone-(radioactive iodine) compound
10/26/2012WO2012142669A1 A method for the treatment of a solid tumour
10/26/2012WO2012119046A3 Heterocyclic compounds for the inhibition of pask
10/26/2012WO2012116357A3 Use of agr3 for treating cancer
10/26/2012WO2012110636A3 Carrier peptides for cell delivery
10/26/2012WO2012104550A3 INHIBITORS OF THE INTERACTION OF THE SIGMA-1 RECEPTOR WITH hERG FOR USE IN THE TREATMENT OF CANCER
10/26/2012WO2012097049A3 Dna repair enzyme inhibitor nanoparticles and uses thereof
10/26/2012WO2012094679A3 Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
10/26/2012WO2012049431A3 Use of an anti-cd20 antibody for treating primary cerebral lymphoma
10/26/2012WO2012027462A9 Compositions and methods for treating neoplasia
10/26/2012WO2012024659A3 Antibody-based constructs directed against tyrosine kinase receptors
10/26/2012WO2012018948A3 Combination therapy for the treatment of prostate carcinoma
10/26/2012WO2011113005A8 Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo)
10/26/2012CA2833766A1 Modulation of hepatitis b virus (hbv) expression
10/26/2012CA2833690A1 Novel binder-drug conjugates (adcs) and their use
10/26/2012CA2833657A1 Triazolopyridines
10/26/2012CA2833643A1 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
10/26/2012CA2833636A1 Antibodies and other molecules that bind b7-h1 and pd-1
10/26/2012CA2833477A1 Novel binder-drug conjugates (adcs) and their use
10/26/2012CA2833413A1 A method for the treatment of a solid tumour
10/26/2012CA2833288A1 Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
10/26/2012CA2833019A1 Prostate-specific membrane antigen binding proteins and related compositions and methods
10/26/2012CA2833009A1 Insulin-like growth factor-1 receptor inhibitors
10/26/2012CA2832866A1 Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same
10/26/2012CA2832860A1 Therapy for leukemia
10/26/2012CA2832763A1 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
10/26/2012CA2832389A1 Bispecific antibodies against her2 and cd3
10/26/2012CA2832387A1 Bispecifc antibodies against her2
10/26/2012CA2832152A1 Anticancer fusion protein
10/26/2012CA2831730A1 A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
10/26/2012CA2831680A1 Heterocyclic compounds as kinase inhibitors
10/26/2012CA2831338A1 Androgen receptor modulating carboxamides
10/26/2012CA2830972A1 Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
10/26/2012CA2828946A1 Therapeutic agent for tumor
10/25/2012US20120272346 Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
10/25/2012US20120270956 Use of protein satb2 as a marker for colorectal cancer
10/25/2012US20120270954 Methods for maintaining eye health and ameliorating opthalmic maladies in canines
10/25/2012US20120270948 Polymorphisims in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications
10/25/2012US20120270940 Closthioamides
10/25/2012US20120270934 Prostacyclin derivatives
10/25/2012US20120270928 Microrna compounds and methods for modulating mir-21 activity
10/25/2012US20120270924 Oligomeric Compounds For The Modultion of HIF-1A Expression
10/25/2012US20120270922 Antiangiogenic Agent and Method for Inhibition of Angiogenesis
10/25/2012US20120270919 Proteasome inhibitors
10/25/2012US20120270918 Pyrazole Derivatives, Preparation Thereof, and Therapeutic Use Thereof
10/25/2012US20120270905 Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof
10/25/2012US20120270900 Novel method of treatment
10/25/2012US20120270897 Acetylene derivatives of 5-phenyl-pyrazolopyridine, preparation thereof, and therapeutic use thereof
1 ... 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 ... 2211